

Cat. No. MHC-HM421F

**Description**

<b>Source</b>	Recombinant FITC-Labeled Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide.
<b>Accession</b>	AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAVGVGK
<b>Molecular Weight</b>	The protein has a predicted MW of 50.3 kDa. Due to glycosylation, the protein migrates to 51-65 kDa based on Bis-Tris PAGE result.
<b>Wavelength</b>	Excitation Wavelength: 490 nm Emission Wavelength: 520 nm
<b>Endotoxin</b>	Less than 1EU per µg by the LAL method.
<b>Purity</b>	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

**Formulation and Storage**


<b>Formulation</b>	Supplied as 0.22µm filtered solution in PBS (pH 7.4).
<b>Storage</b>	Valid for 12 months from date of receipt when stored at -80°C.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

**Background**

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

**Assay Data**


**Bis-Tris PAGE**



FITC-Labeled Human HLA-A\*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

**SEC-HPLC**

Assay Data



The purity of FITC-Labeled Human HLA-A\*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer is greater than 95% as determined by SEC-HPLC.